Apixaban
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Apixaban: Migraine disorder
One-Sentence Summary
Apixaban is a direct factor Xa inhibitor anticoagulant marketed in Canada by many manufacturers. The TxGNN model predicts it for migraine disorder, but the evidence level is L5 (model prediction only). One clinical trial was retrieved and it does not study migraine. The available case reports describe migraine with aura that worsened, or did not resolve, on apixaban.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9902 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 19; dormant: 1) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Apixaban is known as a direct factor Xa inhibitor, which reduces thrombin generation and clot formation.
There is no established mechanistic rationale for apixaban in migraine. One hypothetical link is that anticoagulation might reduce microembolic triggers of aura, as proposed in the patent foramen ovale (paradoxical embolism) hypothesis, or in thrombosis associated with antiphospholipid antibodies. This remains speculative.
The case-level observations point the other way. One report describes migraine with aura worsening after apixaban was started. Another describes aura that resolved on warfarin but not on apixaban. The high score of 0.9902 is a computational output and is not backed by clinical data.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00562289 | Phase 3 | Completed | 664 | Compared PFO closure, anticoagulants and antiplatelet therapy for preventing stroke recurrence. Migraine was not the target population or primary endpoint, and apixaban was not the specific agent studied. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33402037 | 2021 | Retrospective study (75 patients) | Lupus | Antithrombotic therapy in refractory migraine with antiphospholipid antibodies. Apixaban was not clearly the agent studied. |
| 37582651 | 2023 | Case report + literature review | The Neurologist | Migraine with aura worsened after starting apixaban. The literature on direct oral anticoagulants and migraine is scarce and controversial. |
| 28960288 | 2017 | Case report | Headache | Migraine with aura remitted on warfarin, returned within 3 weeks of switching to apixaban, and resolved again after warfarin was resumed. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02527987 | BIO-APIXABAN | Not available | Not available |
| 02486806 | AURO-APIXABAN | Not available | Not available |
| 02510464 | TARO-APIXABAN | Not available | Not available |
| 02484994 | TEVA-APIXABAN | Not available | Not available |
| 02489236 | SANDOZ APIXABAN SDZ | Not available | Not available |
Twenty single-ingredient apixaban licences are listed in the local data (19 valid); this list may be partial. Only five are shown here.
Safety Considerations
- Drug Interactions: 100 interactions were found in total. Major-level interactions include acetylsalicylic acid, cobicistat, deferasirox, ibritumomab tiuxetan, and tositumomab (including I-131). Moderate-level interactions include aprepitant, clarithromycin, clotrimazole, dexamethasone, miconazole, and others.
Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone, so the evidence level is L5. No study supports apixaban for migraine, and the available case reports describe migraine with aura that worsened, or did not resolve, on apixaban.
To proceed, the following is needed:
- Mechanism-of-action data for apixaban and a plausible link to migraine
- Controlled studies of apixaban in migraine, for example in patients with PFO or antiphospholipid antibodies
- Review of the Health Canada package insert for warnings and contraindications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.